argenx SE (NASDAQ:ARGX – Get Rating) – Wedbush decreased their FY2022 earnings estimates for shares of argenx in a research note issued to investors on Monday, January 9th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($18.15) per share for the year, down from their prior forecast of ($16.61). The consensus estimate for argenx’s current full-year earnings is ($15.54) per share. Wedbush also issued estimates for argenx’s Q4 2022 earnings at ($5.69) EPS, Q1 2023 earnings at ($2.35) EPS, Q2 2023 earnings at ($2.50) EPS, Q3 2023 earnings at ($2.65) EPS, Q4 2023 earnings at ($2.68) EPS, FY2023 earnings at ($10.19) EPS, FY2024 earnings at ($8.00) EPS, FY2025 earnings at $3.24 EPS and FY2026 earnings at $32.33 EPS.
ARGX has been the subject of a number of other reports. Evercore ISI raised shares of argenx to an “outperform” rating in a research note on Friday, October 21st. Stifel Nicolaus lifted their price target on shares of argenx from $471.00 to $478.00 and gave the stock a “buy” rating in a research note on Thursday, December 22nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of argenx from €400.00 ($430.11) to €425.00 ($456.99) and gave the stock a “buy” rating in a research note on Thursday, September 22nd. Morgan Stanley boosted their price objective on shares of argenx from $401.00 to $450.00 and gave the company an “overweight” rating in a research report on Friday, October 28th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of argenx from €470.00 ($505.38) to €480.00 ($516.13) and gave the company an “overweight” rating in a research report on Monday, November 14th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $452.83.
argenx Trading Up 2.1 %
argenx (NASDAQ:ARGX – Get Rating) last released its quarterly earnings results on Thursday, October 27th. The company reported ($4.26) EPS for the quarter, missing analysts’ consensus estimates of ($3.50) by ($0.76). argenx had a negative return on equity of 49.53% and a negative net margin of 295.08%. The firm had revenue of $146.49 million for the quarter, compared to analysts’ expectations of $115.49 million.
Institutional Investors Weigh In On argenx
Hedge funds have recently modified their holdings of the business. Parkside Financial Bank & Trust lifted its position in shares of argenx by 144.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 71 shares of the company’s stock worth $25,000 after purchasing an additional 42 shares during the period. Glassman Wealth Services lifted its position in shares of argenx by 69.4% in the 2nd quarter. Glassman Wealth Services now owns 83 shares of the company’s stock worth $31,000 after purchasing an additional 34 shares during the period. KB Financial Partners LLC lifted its position in shares of argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the period. Guardian Wealth Advisors LLC purchased a new stake in shares of argenx in the 3rd quarter worth approximately $31,000. Finally, CWM LLC lifted its position in shares of argenx by 107.3% in the 2nd quarter. CWM LLC now owns 114 shares of the company’s stock worth $43,000 after purchasing an additional 59 shares during the period. Hedge funds and other institutional investors own 57.29% of the company’s stock.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy’s Stock Uptrend Set To Continue?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.